• UCLA Health
  • myUCLAhealth
  • School of Medicine
Institute of Urologic Oncology

UCLA Institute of Urologic Oncology

Institute of Urologic Oncology
  • About Us
    • Director's Welcome
    • Board of Directors
    • IUO in the News
    • Why Choose the UCLA IUO
    • Support the IUO
    • Contact Us
    • The Wasserman Building
    • Maps and Directions
    • IUO Membership Information
    • Administrative & Research Staff
    • Positions Available
  • Clinical Programs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • Testicular Cancer
    • Integrated Cancer Program
    • Cancer Genetic Risk Assessment Program
    • Second Opinion for Cancer
  • Research Programs
    • Clinical Trials
    • Faculty Labs
    • Bladder Cancer
    • Kidney Cancer
    • Prostate Cancer
    • LuPSMA Risk Calculator
    • PSMA Risk Calculator
    • SPORE In Prostate Cancer
    • Webinars / Videos
  • Clinical Trials
    • What Is a Clinical Trial?
    • Who Should Consider Clinical Trials & Why
    • Bladder Cancer Clinical Trials
    • Kidney Cancer Clinical Trials
    • Prostate Cancer Clinical Trials
    • Testicular Cancer Clinical Trials
    • Clinical Research Team
    • IUO Membership Study Information
  • For Patients
    • Contact Us
    • Clinical Updates
    • Maps and Directions
    • myUCLAhealth
    • Webinars / Videos
  • Fellowship
    • Current Fellows
    • Former Fellows
    • Fellow Testimonials
    • UCLA Health Aerial Tour
    • Webinars/Videos
  • For Healthcare Professionals
    • How to Refer a Patient
    • Lectures & Conferences
    • CTSI Distinguished Speaker Seminar Series
    • DGSOM Research Seminars
    • DGSOM Events
    • JCCC Seminars
    • Researcher Resources
    • SPORE Lectures
  • Expert Team
    • Board of Directors
    • Medical Oncology
    • Nuclear Medicine
    • Pathology
    • Radiation Oncology
    • Radiology
    • Urologic Oncology
    • Research Faculty
    • Emeritus Faculty
  • UCLA Health
  • myUCLAhealth
  • School of Medicine

UCLA Institute of Urologic Oncology

Research Programs

Research Programs

Research Programs

  • Clinical Trials
  • Faculty Labs
    • Dr. Corey Arnold Lab
      • Meet Our Team
      • Publications
    • Dr. Paul Boutros Lab
      • Research Areas
      • Meet Our Team
      • Publications
    • Dr. Jeremie Calais Lab
      • Research Areas
      • Meet Our Team
      • Publications
      • Videos
    • Dr. Karim Chamie Lab
      • Meet Our Team
      • Publications
    • Dr. Andrew Goldstein Lab
      • Research Areas
      • Meet Our Team
      • Publications
    • Dr. William Hsu Lab
      • Meet Our Team
      • Publications
    • Dr. Amar Kishan Research
      • Meet Our Team
      • Publications
    • Drs. Lueckerath/Mona Lab
      • Meet Our Team
      • Publications
    • Dr. Leonard S Marks Lab
      • Meet Our Team
      • Publications
    • Dr. Robert Reiter Lab
      • Meet Our Team
      • Publications
    • Dr. Lily Wu Lab
      • Meet Our Team
      • Publications
  • Bladder Cancer
  • Kidney Cancer
    • Unique Tumor Repository Launched
  • Prostate Cancer
  • LuPSMA Risk Calculator
  • PSMA Risk Calculator
  • SPORE In Prostate Cancer
  • Webinars / Videos
  • Clinical Trials
  • Faculty Labs
  • Bladder Cancer
  • Kidney Cancer
  • Prostate Cancer
  • LuPSMA Risk Calculator
  • PSMA Risk Calculator
  • SPORE In Prostate Cancer
  • Webinars / Videos
  • Dr. Corey Arnold Lab
  • Dr. Paul Boutros Lab
  • Dr. Jeremie Calais Lab
  • Dr. Karim Chamie Lab
  • Dr. Andrew Goldstein Lab
  • Dr. William Hsu Lab
  • Dr. Amar Kishan Research
  • Drs. Lueckerath/Mona Lab
  • Dr. Leonard S Marks Lab
  • Dr. Robert Reiter Lab
  • Dr. Lily Wu Lab
  • Meet Our Team
  • Publications
  1. Home
  2. Institute of Urologic Oncology
  3. Research Programs
  4. Faculty Labs
  5. Dr. Karim Chamie Lab

Dr. Karim Chamie Lab

Share this

Chamie Research

Profile

Karim Chamie, MD, MSHS

Associate Professor
UCLA Department of Urology

Director, IUO Bladder Cancer Program
Director, IUO Fellowship Program
Director, Urologic Oncology Fellowship Program


The Chamie Lab’s current translational research focuses on the local delivery of immunotherapy for the treatment of non-muscle invasive bladder cancer, as well as the investigation of opioid receptors as prognostic markers and therapeutic targets in urothelial carcinoma (UC).

Utilizing a murine orthotopic bladder cancer model, the lab is evaluating the ability of several immunotherapeutic agents to penetrate the urothelium and enter the tumor microenvironment. Tumors treated with an intravesical instillation of anti-programmed cell death protein-1 (PD-1) monoclonal antibodies have been evaluated with immunofluorescence and immunohistochemistry to attempt to demonstrate the presence of drug within the tumor microenvironment. Ongoing work is assessing treatment response to intravesical PD-1 inhibitors in combination with immune stimulators, such as toll-like receptor agonists, with in-vivo immunofluorescence for evaluation of tumors size, and flow cytometry and immunohistochemistry on local immune response. This work aims to inform future clinical trial design a novel drug development.

The impact of opioid drugs on cancer biology is a burgeoning area of interest in the lab. An institutional tissue microarray of urothelial carcinoma specimens was assessed for expression of the mu-opioid receptor, and demonstrated a significant inverse association between receptor expression and tumor aggressiveness. In vitro studies assessing the influence of opioid receptor agonists, and antagonists, on urothelial carcinoma cell lines are underway and preliminarily demonstrate this receptor to be a possible druggable target.

Outside the lab, Dr Chamie’s health services research group studies the quality of care delivered to patients with urologic malignancies, with a focus on bladder cancer. Recent work has evaluated the role of lymphadenectomy in patients undergoing radical cystectomy in non-muscle invasive bladder cancer, management trends in the surgical treatment of upper tract urothelial carcinoma, and partial cystectomy utilization trends. With the support of a grant from the American Urological Association, this group is developing and validating a symptom questionnaire for patients undergoing intravesical treatment of non-muscle invasive bladder cancer.

Publications > | Meet Our Team >

Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest
UCLA Health hospitals ranked best hospitals by U.S. News & World Report
  • UCLA Health
  • Find a Doctor
  • School of Medicine
  • School of Nursing
  • UCLA Campus
  • Directory
  • Newsroom
  • Subscribe
  • Patient Stories
  • Giving
  • Careers
  • Volunteer
  • International Services
  • Privacy Practices
  • Nondiscrimination
  • Billing
  • Health Plans
  • Emergency
  • Report Broken Links
  • Terms of Use
  • 1-310-825-2631
  • Maps & Directions
  • Contact Us
  • Your Feedback
  • Report Misconduct
  • Get Social
  • Sitemap
Like Us on Facebook Follow Us on Twitter Subscribe to Our Videos on YouTube Follow us on Instagram Connect with Us on LinkedIn Follow us on Pinterest